Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists.

Rasmussen VG, Østergaard K, Dupont E, Poulsen SH.

Mov Disord. 2011 Apr;26(5):801-6. Review.

PMID:
21671508
2.

[Valvular heart disease associated with the treatment of Parkinson disease].

Rasmussen VG, Dupont E, Østergaard K, Egeblad H.

Ugeskr Laeger. 2006 Jun 26;168(26-32):2542-4. Review. Danish.

PMID:
16824407
3.

Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.

N Engl J Med. 2007 Jan 4;356(1):39-46.

4.

Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.

Simonis G, Fuhrmann JT, Strasser RH.

Mov Disord. 2007 Oct 15;22(13):1936-42.

PMID:
17659636
5.

Dopamine agonists and the risk of cardiac-valve regurgitation.

Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E.

N Engl J Med. 2007 Jan 4;356(1):29-38.

6.

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.

Kim JY, Chung EJ, Park SW, Lee WY.

Mov Disord. 2006 Aug;21(8):1261-4.

PMID:
16685692
7.

Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.

Trifirò G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, Herings R, de Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, van Camp G, Zanettini R, Sturkenboom MC.

Drug Saf. 2012 Feb 1;35(2):159-71. doi: 10.2165/11594940-000000000-00000.

PMID:
22204718
8.

Dopamine agonists and valvular heart disease.

Cheung D, Heaney A.

Curr Opin Endocrinol Diabetes Obes. 2009 Aug;16(4):316-20. doi: 10.1097/MED.0b013e32832d9f64. Review.

PMID:
19506475
9.

Bromocriptine use and the risk of valvular heart disease.

Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC.

Mov Disord. 2009 Feb 15;24(3):344-9. doi: 10.1002/mds.22228.

PMID:
18989898
10.

Dopamine agonists and valvular heart disease.

Linkova H, Ruzicka E, Penicka M.

N Engl J Med. 2007 Apr 19;356(16):1676; author reply 1678-80. No abstract available.

PMID:
17447279
11.

Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.

Rasmussen VG, Poulsen SH, Dupont E, Østergaard K, Safikhany G, Egeblad H.

J Intern Med. 2008 Jan;263(1):90-8. Epub 2007 Nov 23.

12.

High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.

Oeda T, Masaki M, Yamamoto K, Mizuta E, Kitagawa N, Isono T, Taniguchi S, Doi K, Yaku H, Yutani C, Kawamura T, Kuno S, Sawada H.

J Neural Transm (Vienna). 2009 Feb;116(2):171-8. doi: 10.1007/s00702-008-0160-2. Epub 2008 Dec 10.

PMID:
19082526
13.

Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.

Steiger M, Jost W, Grandas F, Van Camp G.

J Neural Transm (Vienna). 2009 Feb;116(2):179-91. doi: 10.1007/s00702-008-0179-4. Epub 2009 Jan 14. Review.

PMID:
19142570
14.
15.

Dopaminagonists and fibrotic valvular heart disease: further considerations.

Rascol O, Pathak A, Bagheri H, Montastruc JL.

Mov Disord. 2004 Dec;19(12):1524-5. No abstract available.

PMID:
15515031
16.

Pergolide associated cardiac valvulopathy based on Ontario administrative data.

Zadikoff C, Duong-Hua M, Sykora K, Marras C, Lang A, Rochon P.

Can J Neurol Sci. 2008 May;35(2):173-8.

PMID:
18574930
17.

Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.

Chaudhuri KR, Dhawan V, Basu S, Jackson G, Odin P.

Mov Disord. 2004 Dec;19(12):1522-3. No abstract available.

PMID:
15515009
18.

[Pergolide use and heart valve fibrosis. Yearly control in patients with Parkinson disease who use pergolide].

van Laar T, Berendse H, Bloem BR, Boon AJ, van Hilten JJ, Hovestadt A, de Koning-Tijssen MA, Nijssen PC, Weber WE.

Ned Tijdschr Geneeskd. 2009 Jan 17;153(3):87-90. Dutch. No abstract available.

PMID:
19235345
19.

[Cardiac valvulopathy and dopamine agonist].

Grandas F.

Neurologia. 2007 Dec;22(10):870-81. Review. Spanish.

PMID:
17671852
20.

Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.

Corvol JC, Anzouan-Kacou JB, Fauveau E, Bonnet AM, Lebrun-Vignes B, Girault C, Agid Y, Lechat P, Isnard R, Lacomblez L.

Arch Neurol. 2007 Dec;64(12):1721-6. Review.

PMID:
18071034

Supplemental Content

Support Center